Kim Ribeiro, MLS, MS

Chief Client Officer

Kim Ribeiro is a highly accomplished pharmaceutical leader with over 15 years of experience in drug development. Renowned for her expertise in multicultural patient recruitment and retention, Kim has consistently delivered top-quartile performance, with 85% of the pivotal clinical trials she’s led completing on time or ahead of timelines and with representative trial populations. As an early advocate for patient-focused drug development, she has pioneered the integration of patient and healthcare provider insights into clinical trial protocols, helping drive more inclusive and effective research practices.

Kim joins Inside Edge with a wealth of experience in clinical operations and transformational leadership. She led organizational change and growth across various sectors, including clinical laboratories, cancer centers, contract research organizations (CROs), and pharmaceutical sponsors. Her ability to establish and scale new strategic functions has been key to future-proofing organizations, ensuring they remain agile and adaptive in a rapidly evolving industry. Passionate about health equity, Kim is driven by the need for the pharmaceutical industry to enhance community engagement in clinical research. At Inside Edge, she is focused on realizing this opportunity and advancing inclusive clinical practices. Kim brings a deep commitment to data-driven decision-making, navigating complex regulatory landscapes, and employing strategic storytelling,

Kim holds a Bachelor’s degree in Biotechnology from Penn State University and a Master’s degree in Biotechnology Management from the University of Maryland. Additionally, Kim serves as an Adjunct Associate Professor in the Clinical Research Management Master’s program at Rutgers University.

In addition to her academic and professional accomplishments, Kim is a licensed Medical Technologist and has been recognized as one of the American Society for Clinical Pathology’s (ASCP) Top 40 Under 40 global medical technology professionals. A published author and an executive faculty member for several conferences, she was named one of PharmaVoice’s Top 100 in both 2023 and 2024 for her contributions to the pharmaceutical industry.

A native New Yorker, Kim enjoys traveling, hosting, and indulging in her love of all things cats.

What does “Make well known” mean to me?

To me, it means leveraging established platforms and trusted voices to shift the narrative on health, making it not just a conversation among experts, but one that includes diverse communities and empowers individuals to take ownership of their well-being.